Tumour necrosis factor-alpha levels as predictor factor on clinical response of anthracycline-based neoadjuvant chemotherapy in locally advance breast cancer patients: experimental research.

Abstract

Analysing TNF-α levels as a predictor factor on clinical response anthracycline-based neoadjuvant chemotherapy. This study design used observational analysis. The length of study was carried out in the period from May 2021 to June 2022. The study procedure included measuring participants' TNF-α levels the day before chemotherapy was carried out and clinical response. Participants received anthracycline-based neoadjuvant chemotherapy (cyclophosphamide of 500mg/m2, doxorubicin of 50mg/m2 and fluorouracil/5FU of 500mg/m2) for 3 cycles. The study analysis used the Chi-square, logistic regression and Spearman's test with P<0.05. The average TNF-α levels was 137.2±311.8pg/ml, ranging from 5.74 to 1.733pg/ml. The results of the calculation of the cutoff value of TNF-α in the study were 18635pg/ml (area under curve =0.850; 95% CI =0.729-0.971). Based on cutoff 1, most participants with high TNF-α levels also had a negative response of 83.3% and those with low TNF-α levels also had a positive response of 75% (P<0.001). Meanwhile, at cutoff 2, similar conditions were also found, namely high TNF-α levels, negative response (84.2%) and low TNF-α levels, positive response (78.9%; P<0.001). The statical analysis showed a significant association of TNF-α levels on the clinical response of chemotherapy, which showed r=-0.606 and P<0.001. TNF-α levels predict clinical response for anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.